Brown Brothers Harriman & CO Immuno Gen, Inc. Transaction History

Brown Brothers Harriman & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$3.15 - $5.76 $447 - $817	-142 Reduced 52.99%	126 $1,000
Q1 2022 May 13, 2022	SELL	$4.26 - $7.48 $95,850 - $168,300	-22,500 Reduced 98.82%	268 $1,000
Q1 2021 May 13, 2021	SELL	$6.5 - $10.53 $16,250 - $26,325	-2,500 Reduced 9.89%	22,768 $184,000
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $93,491 - $193,552	25,268 New	25,268 $163,000
Q2 2020 Aug 13, 2020	SELL	$3.32 - $5.34 $913 - $1,468	-275 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $583 - $1,870	275 New	275 $1,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $297 - $454	-134 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $64 - $118	36 Added 36.73%	134 $0
Q1 2019 May 15, 2019	SELL	$2.41 - $5.91 $103 - $254	-43 Reduced 30.5%	98 $0
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $1,212 - $1,587	141 New	141 $1,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

Stay updated on Brown Brothers Harriman & CO with notifications on news.